China Resources Double-Crane Pharmaceutical Co (SHSE:600062) Moat Score: 0/10 (As of Jul. 09, 2026)


SHSE:600062 China Resources Double-Crane Pharmaceutical Co Ltd SHSE:600062
90 GF Score
Price ¥16.43
GF Value ¥18.75
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is China Resources Double-Crane Pharmaceutical Co Moat Score?

China Resources Double-Crane Pharmaceutical Co has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

China Resources Double-Crane Pharmaceutical Co has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes China Resources Double-Crane Pharmaceutical Co might have No Moat - No discernible moat.

China Resources Double-Crane Pharmaceutical Co  (SHSE:600062) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

China Resources Double-Crane Pharmaceutical Co Moat Score Related Terms

SHSE:600062
90GF Score
China Resources Double-Crane Pharmaceutical Co Ltd SHSE:600062
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is China Resources Double-Crane Pharmaceutical Co (SHSE:600062) Overvalued in 2026?

Based on GuruFocus' analysis, China Resources Double-Crane Pharmaceutical Co stock appears to be undervalued. The current stock price of ¥16.43 is trading 12.4% below its estimated GF Value™ of ¥18.75. GuruFocus considers China Resources Double-Crane Pharmaceutical Co to be Modestly Undervalued.

Key valuation signals for SHSE:600062:

  • Moat Score: 0
  • GF Value™: ¥18.75 vs. price of ¥16.43 (12.4% below fair value)
  • GF Score™: 90/100 with 4 warning signs

No single metric tells the full story. See the SHSE:600062 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

China Resources Double-Crane Pharmaceutical Co Business Description

Address No. 1, East Second Road, Lijing, Wangjing, Chaoyang District, Beijing, CHN, 100102
China Resources Double-Crane Pharmaceutical Co Ltd is a China-based pharmaceutical company. It is engaged in developing, manufacturing and marketing a variety of medical products. The company's products cover different fields such as infusion field, cardiovascular and cerebrovascular fields, pediatrics, endocrine field and other areas.
90GF Score

Get the complete analysis for SHSE:600062

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥16.43
Price
¥18.75
GF Value